Contract Win

20 July 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

£0.5m contract win for Research business

The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies for cognitive assessment, today announced that it has secured its largest contract to date for the CANTAB Connect Research^® product, which is marketed for use in research projects by academic and small biotechnology research groups ("the Contract").

Worth an estimated £0.5 million, the Contract is the Company's first with an international biobank and the highest recorded sale of its research software. Biobanks amass large amounts of data and biological samples and catalogue them according to genetic, biological, environmental and other traits. These data and samples are then made available for researchers to support medical research in many fields. There are over 300 biobanks globally and the addition of neurological health data generated using Cambridge Cognition products will help to progress research into prevalent health issues, now and in the future.

The Contract allows for unlimited assessments to be conducted using the Company's proprietary touchscreen cognitive tests based on over 30 years of peer-reviewed science. The software will generate data that will be used for medical research to assess mental health in a general population over the next five years.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition: "Biobanks play a crucial role in biomedical research, enabling pharmaceutical companies to translate research into better treatments. We are therefore excited to be working in partnership with biobanks internationally, helping them advance drug development by enhancing their research capabilities."

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

Enquiries

Notes to editors

About Cambridge Cognition

Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.

For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and monitor and manage cognitive health throughout life.

Partners include the world's leading biotechnology and pharmaceutical companies; leading academic institutions; and public-private healthcare providers.

www.cambridgecognition.com